Law Office of Brodsky & Smith, LLC Announces Investigation of DUSA Pharmaceuticals, Inc.

  Law Office of Brodsky & Smith, LLC Announces Investigation of DUSA
  Pharmaceuticals, Inc.

Business Wire

BALA CYNWYD, Pa. -- November 14, 2012

Law office of Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of DUSA Pharmaceuticals, Inc.
(“DUSA” or the “Company”) (Nasdaq: DUSA) relating to the proposed acquisition
by Sun Pharmaceutical Industries Ltd. (“Sun”).

Under the terms of the transaction, DUSA shareholders will receive only $8.00
in cash for each share of DUSA stock they own. The investigation concerns
possible breaches of fiduciary duty and other violations of state law by the
Board of Directors of DUSA for not acting in the Company’s shareholders' best
interests in connection with the sale process to Sun. The transaction may
undervalue the Company and will not result in any substantial gain for many
DUSA shareholders as DUSA stock traded at $7.00 on October 16, 2012. In
addition, an analyst has set a $9.50 per share price target for DUSA.

If you own shares of DUSA stock and wish to discuss the legal ramifications of
the proposed transaction, or have any questions, you may e-mail or call the
law office of Brodsky & Smith, LLC who will, without obligation or cost to
you, attempt to answer your questions. You may contact Jason L. Brodsky,
Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza,
Suite 602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com visiting
http://brodsky-smith.com/501-dusa-dusa-pharmaceuticals-inc.html, by calling
toll free 877-LEGAL-90.

Contact:

Brodsky & Smith, LLC
Jason L. Brodsky, Esquire
Evan J. Smith, Esquire
877-LEGAL-90
investorrelations@brodsky-smith.com
http://brodsky-smith.com/501-dusa-dusa-pharmaceuticals-inc.html
 
Press spacebar to pause and continue. Press esc to stop.